We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

Share Price Information for Tissue Regenix Group (TRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 61.50
Bid: 61.00
Ask: 62.00
Change: 0.00 (0.00%)
Spread: 1.00 (1.639%)
Open: 62.00
High: 62.00
Low: 61.50
Prev. Close: 61.50
TRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company

26 Oct 2020 16:50

RNS Number : 2486D
Tissue Regenix Group PLC
26 October 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

TISSUE REGENIX GROUP PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Harwood Capital Management (Gibraltar) Limited (as investment adviser/manager) to 1.Oryx International Growth Fund Limited

and Harwood Capital LLP (as investment advisor/manager) to 2. Harwood Capital LLP

City and country of registered office (if applicable)

1. Guernsey

2. London, United Kingdom

 

4. Full name of shareholder(s) (if different from 3.)v

Name

1. Oryx International Growth Fund Limited

2. Harwood Capital LLP

 

City and country of registered office (if applicable)

As above

5. Date on which the threshold was crossed or reachedvi:

23/10/2020

6. Date on which issuer notified (DD/MM/YYYY):

26/10/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

 

1. 4.16%

2. 0.18%

 

 

1. 4.16%

2. 0.18%

 

7,032,985,756

Position of previous notification (if

applicable)

1. 2.99%

2. 0.18%

 

 

1. 2.99%

2. 0.18%

 

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00B5SGVL29

 

 

1. 292,700,828

2. 12,500,000

 

 

1. 4.16%

2. 0.18%

 

SUBTOTAL 8. A

305,200,828

4.34%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

x

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Christopher Harwood Bernard Mills

4.16%

0

4.16%

Harwood Capital Management Ltd

Harwood Capital LLP

Oryx International Growth Fund Ltd

Christopher Harwood Bernard Mills

0.18%

0

0.18%

Harwood Capital Management Ltd

Harwood Capital LLP

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London

Date of completion

26th October 2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEAKEKADNEFFA
Date   Source Headline
10th Sep 20149:00 amRNSdCELL® technology presented at Royal Society event
30th Jul 20147:00 amRNSUK meniscus clinical trial & DermaPure US updates
25th Jul 20147:00 amRNSTissue Regenix adds European bladder matrix patent
18th Jul 201411:11 amRNSIssue of equity and total voting rights
27th Jun 20143:06 pmRNSResult of AGM
12th Jun 20147:00 amRNSTissue Regenix announces launch of DermaPure in US
22nd May 20147:00 amRNSPreliminary Decision to Approve "Q" Code Request
20th May 20147:00 amRNSDeferred Annual Bonus Award
19th May 201410:21 amRNSAnnual Report & Accounts and Notice of AGM
19th May 20147:00 amRNSPreliminary results for year ended 31 January 2014
16th May 20141:00 pmRNSTissue Regenix adds US patent
12th May 201411:00 amRNSNotice of Preliminary Results
30th Apr 20145:14 pmRNSHolding(s) in Company
28th Apr 20147:00 amRNSTissue Regenix adds Chinese patent
24th Apr 20148:40 amRNSHolding(s) in Company
4th Feb 20143:03 pmRNSIssue of Share Options
31st Jan 20141:11 pmRNSHolding(s) in Company
14th Jan 20145:22 pmRNSIssue of equity and total voting rights
9th Jan 201411:11 amRNSIssue of equity and total voting rights
19th Dec 20137:00 amRNSTissue Regenix to attend JPMorgan Healthcare Event
12th Dec 20137:00 amRNSTissue Regenix signs US distribution agreements
22nd Nov 20137:00 amRNSDirector Share Purchase
29th Oct 20137:00 amRNSPresentation at Proactiveinvestors Forum in Dublin
28th Oct 20134:49 pmRNSDirector Share Purchase
21st Oct 20137:00 amRNSPublication of DermaPure UK trial results
17th Oct 20134:41 pmRNSHolding(s) in Company
17th Oct 20134:41 pmRNSHolding(s) in Company
17th Oct 20134:41 pmRNSHolding(s) in Company
14th Oct 20137:00 amRNSTissue Regenix USA successful technology transfer
8th Oct 20137:00 amRNSInterim Results for six months ended 31 July 2013
12th Aug 20137:00 amRNSTissue Regenix USA Appoints VP of Marketing
6th Aug 20139:41 amRNSHolding(s) in Company
5th Aug 20137:00 amRNSTissue Regenix USA Appoints VP of Operations
29th Jul 20138:45 amRNSTissue Regenix Key Appointment at USA Subsidiary
25th Jul 20134:59 pmRNSHolding(s) in Company
17th Jul 20137:00 amRNSAppointment of Non-Executive Director
10th Jul 20137:00 amRNSAppointment of Non-Executive Director
18th Jun 20137:00 amRNSTissue Regenix advances US commercialisation
14th Jun 201312:43 pmRNSResult of AGM
14th Jun 20137:00 amRNSPresentation of dCELL at heart valve event
28th May 20137:00 amRNSAppointment of Business Development Manager
14th May 20133:47 pmRNSAnnual Report and Notice of AGM
13th May 20137:00 amRNSPreliminary results for the year ended 31 Jan 2013
3rd May 20137:00 amRNSNotice of Results
2nd May 20137:00 amRNSResults of dCELL Dermis trial
29th Apr 20137:00 amRNSChange of Nominated Adviser and Broker
16th Apr 20137:00 amRNSApproval for start of clinical research trial
2nd Apr 20137:00 amRNSTissue Regenix makes appointment to US subsidiary
11th Mar 20137:00 amRNSDirector Change
15th Feb 20132:38 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.